Multi-Omics Analysis of Survival-Related Splicing Factors and Identifies CRNKL1 as a Therapeutic Target in Esophageal

Tianrui Gao1,2, Meiling Fan1,2, Zhongyuan Zeng3

  • 1State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Genes
|April 26, 2025
PubMed

Insights

Six survival-related splicing factors (SFs) drive esophageal cancer aggressiveness by promoting stemness and metastasis. Their targets, including CD44 and CTTN, offer potential therapeutic strategies for this cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • RNA alternative splicing is crucial for gene expression, with splicing factors (SFs) as key regulators.
  • Dysregulated SFs contribute to cancer by producing oncogenic splice variants, but their roles are not fully understood.
  • Esophageal cancer progression is linked to aberrant SF activity.

Purpose of the Study:

  • Identify survival-related SFs in esophageal cancer.
  • Elucidate their biological networks and downstream targets.
  • Investigate their role in tumor aggressiveness and identify therapeutic vulnerabilities.

Main Methods:

  • Multi-omics analysis to identify SFs and their networks in esophageal cancer.
  • Combined SF knockdown splicing events with cancer-specific splicing events.
  • Validated splicing events using full-length RNA sequencing in cell lines and clinical samples.

Main Results:

  • Identified six highly expressed SFs correlating with poor esophageal cancer prognosis.
  • These SFs are linked to immune infiltration, cancer stemness, heterogeneity, and drug resistance.
  • CRNKL1 identified as a hub SF; CD44 and CTTN alternative splicing regulated by SFs, correlating with poor prognosis.

Conclusions:

  • Unveiled six survival-related SFs driving esophageal cancer aggressiveness.
  • CTTN and CD44 alternative splicing are common downstream effectors of these SFs.
  • Provides mechanistic insights into SF-mediated tumorigenesis and highlights therapeutic targets in esophageal cancer.